Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | WNT1 | P04628 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778751 | 1.00 | GSK3B (0.35) | GSK3BDYRK1AHRH3PDK1PDK2 | |
| SCHEMBL17768043 | 0.89 | GSK3B (0.44) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19689740 | 0.89 | GSK3B (0.44) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19689693 | 0.89 | DYRK1A (0.34) | GSK3BDYRK1APDK1PDK2PDK3 | |
| SCHEMBL17778384 | 0.87 | L3MBTL1 (0.35) | IRAK4WNT3AUSP30 | |
| SCHEMBL16754615 | 0.87 | L3MBTL1 (0.35) | IRAK4WNT3AUSP30 | |
| SCHEMBL19689662 | 0.87 | GSK3B (0.39) | GSK3BDYRK1AIRAK4WNT1WNT3A | |
| SCHEMBL17768105 | 0.87 | GSK3B (0.36) | GSK3BDYRK1AHRH3IRAK4WNT1 | |
| SCHEMBL17778671 | 0.86 | EGFR (0.43) | DYRK1AEGFRIRAK4 | |
| SCHEMBL17770414 | 0.86 | GSK3B (0.35) | GSK3BDYRK1AEGFRWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2322/4885DYRK1A 3048/4885HRH3 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.